Haleon (LON:HLN) Earns Underweight Rating from JPMorgan Chase & Co.

Key Points

• Haleon's stock has been reissued an "underweight" rating by JPMorgan Chase & Co., indicating a cautious outlook from the bank's analysts.
• Royal Bank of Canada has set a target price of GBX 370 ($4.89) for Haleon shares, maintaining its "sector perform" rating.
• Insider trading activity shows significant transactions, with Dawn Allen selling 64,329 shares and Marie-Anne Aymerich purchasing 21,300 shares recently.

Haleon (LON:HLN - Get Free Report)'s stock had its "underweight" rating reaffirmed by equities research analysts at JPMorgan Chase & Co. in a research note issued to investors on Friday, Marketbeat.com reports.

Separately, Royal Bank Of Canada reiterated a "sector perform" rating and set a GBX 370 ($4.92) target price on shares of Haleon in a research report on Thursday, July 31st.

Haleon Trading Down 1.7%

LON:HLN traded down GBX 6 ($0.08) during trading hours on Friday, hitting GBX 349.80 ($4.65). 23,181,637 shares of the stock were exchanged, compared to its average volume of 25,361,586. The company's 50 day moving average is GBX 380.59 and its two-hundred day moving average is GBX 385.18. The company has a market capitalization of £31.57 billion, a P/E ratio of 29.42, a price-to-earnings-growth ratio of 1.49 and a beta of 0.19. Haleon has a twelve month low of GBX 346.10 ($4.60) and a twelve month high of GBX 419.50 ($5.58). The company has a quick ratio of 0.93, a current ratio of 0.84 and a debt-to-equity ratio of 53.36.

Haleon (LON:HLN - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported GBX 8.90 ($0.12) EPS for the quarter. Haleon had a net margin of 9.66% and a return on equity of 6.54%. On average, sell-side analysts anticipate that Haleon will post 19.5033282 earnings per share for the current fiscal year.

Insider Activity at Haleon

In other news, insider Blathnaid Bergin acquired 6,145 shares of the stock in a transaction that occurred on Friday, May 16th. The stock was acquired at an average price of GBX 404 ($5.37) per share, for a total transaction of £24,825.80 ($32,995.48). Also, insider Dawn Allen sold 64,329 shares of the company's stock in a transaction on Monday, June 30th. The shares were sold at an average price of GBX 376 ($5.00), for a total transaction of £241,877.04 ($321,474.00). 10.74% of the stock is owned by corporate insiders.

About Haleon

Haleon LSE / NYSE: HLN is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other.